Table 1 Demographics, medications and disease activity for RA patients and controls
Clinical features | Early RA | Late RA | Healthy controls |
|---|---|---|---|
(n = 15) | (n = 13) | (n = 15) | |
Age, yrs (median, range) | 57 (36 to 87) | 69 (43 to 84) | 51 (37 to 62) |
Female: male | 11:4 | 8:5 | 13:2 |
Duration of RA, months | 54 (48 to 72) | 240 (83 to 456) | |
Ethnicity: Caucasian (%) | 87 | 85 | 87 |
Anti-CCP antibody + VE (%) | 93 | 92 | |
RF positive (%) | 60 | 69 | |
Medications – No. (%) | |||
NSAIDs | 4 (27) | 3 (23) | |
MTX alone* | 3 | 1 | |
cDMARD combinations** | |||
MTX, SSZ, HCQ | 0 | 2 | |
MTX, HCQ, LEF | 1 | 0 | |
MTX, LEF | 2 | 0 | |
MTX, LEF, HCQ | 0 | 1 | |
MTX, LEF, SSZ | 1 | 0 | |
MTX, SSZ | 0 | 2 | |
MTX, HCQ | 3 | 1 | |
MTX, IM gold, LEF | 0 | 1 | |
HCQ, LEF | 1 | 0 | |
Prednisone 2.5 to 10 mg/d | 4 (27) | 2 (15) | |
bDMARDs*** | 1 (7) | 4 (31) | |
ETC | 1 | 1 | |
ADA | 0 | 3 | |
Disease activity (median, range) | |||
Tender joint count (68) | 8 (1 to 36) | 17 (0 to 40) | |
Swollen joint count (66) | 1 (0 to 6) | 3 (0 to 8) | |
Pain VAS (mm) | 14 (2 to 91) | 20 (0 to 47) | |
Global VAS (mm) | 2 (0 to 4) | 2 (0 to 3) | |
HAQ score | 0.75 (0 to 1.75) | 0.88 (0 to 2.5) | |
PF SF - 36 | 65 (5 to 100) | 65 (5 to 95) | |
CRP (mg/l) | 2 (1 to 36) | 4 (1 to 13) | 1.2 (1 to 9) |
DAS28CRP3v | 3.1 (1.5 to 4.8) | 3.6 (1.9 to 4.8) | |